﻿<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
  <channel>
    <title>CPhI-Online.com</title>
    <link>http://www.cphi-online.com/</link>
    <item>
      <link>http://www.cphi-online.com/news/16335/Avalanche+%26+Lonza+to+Collaborate+on+Adeno-associated+Viral+Vectors.html</link>
      <title>Avalanche &amp; Lonza to Collaborate on Adeno-associated Viral Vectors</title>
      <author>joe | CPhI-Online.com</author>
      <category />
      <pubDate>Fri, 18 May 2012 09:13:02</pubDate>
      <description><![CDATA[Avalanche and Lonza are partnering up to develop and manufacture AAV vectors for the treatment of eye diseases such as macular degeneration.]]></description>
    </item>
    <item>
      <link>http://www.cphi-online.com/news/16336/Human+Genome+Sciences+Brands+GSK+Tender+Offer+'Inadequate'.html</link>
      <title>Human Genome Sciences Brands GSK Tender Offer 'Inadequate'</title>
      <author>joe | CPhI-Online.com</author>
      <category />
      <pubDate>Fri, 18 May 2012 17:52:00</pubDate>
      <description><![CDATA[HGS has urged stockholders not to tender their shares to GSK following the pharmaceutical giant's 'inadequate' tender offer.]]></description>
    </item>
    <item>
      <link>http://www.cphi-online.com/news/16334/Breast+Cancer+Pipeline+Remains+Strong%2c+Analysts+Say.html</link>
      <title>Breast Cancer Pipeline Remains Strong, Analysts Say</title>
      <author>joe | CPhI-Online.com</author>
      <category />
      <pubDate>Thu, 17 May 2012 17:50:45</pubDate>
      <description><![CDATA[A new report from Frost & Sullivan has highlighted the unmet need for breast cancer therapies.]]></description>
    </item>
    <item>
      <link>http://www.cphi-online.com/news/16331/GSK+to+Fully+Acquire+Cellzome.html</link>
      <title>GSK to Fully Acquire Cellzome</title>
      <author>joe | CPhI-Online.com</author>
      <category />
      <pubDate>Wed, 16 May 2012 13:23:01</pubDate>
      <description><![CDATA[<img src="/Upload/news/2012_05/Nimg_12051613260C46D2.jpg" width="180" />GSK took an initial 19.98% stake in Cellzome in 2008 and will now purchase the remaining 80.02% shares in the company.]]></description>
    </item>
    <item>
      <link>http://www.cphi-online.com/news/16323/IPEC+Foundation+to+Establish+IPEC+India.html</link>
      <title>IPEC Foundation to Establish IPEC India</title>
      <author>Suja Nair Shirodkar | CPhI-Online.com</author>
      <category />
      <pubDate>Tue, 15 May 2012 15:35:33</pubDate>
      <description><![CDATA[<img src="/Upload/news/2012_05/Nimg_12051515395743C7.jpg" width="180" />IPEC intends to play an instrumental role in sensitising the Indian excipient manufacturers and exporters about its guidelines which is globally accepted by top regulators across the world.]]></description>
    </item>
    <item>
      <link>http://www.cphi-online.com/news/16313/Arena+%26+Eisai+Expand+Lorcaserin+Marketing+%26+Supply+Agreement.html</link>
      <title>Arena &amp; Eisai Expand Lorcaserin Marketing &amp; Supply Agreement</title>
      <author>joe | CPhI-Online.com</author>
      <category />
      <pubDate>Mon, 14 May 2012 10:35:05</pubDate>
      <description><![CDATA[Arena and Eisai have announced an expansion to their original marketing and supply agreement for weight-loss drug candidate lorcaserin.]]></description>
    </item>
    <item>
      <link>http://www.cphi-online.com/news/16316/Pharmaceuticals+Industry+Sees+Spate+of+M%26A+Activity.html</link>
      <title>Pharmaceuticals Industry Sees Spate of M&amp;A Activity</title>
      <author>joe | CPhI-Online.com</author>
      <category />
      <pubDate>Mon, 14 May 2012 11:07:01</pubDate>
      <description><![CDATA[Some $33 billion of M&A activity took place among pharmaceuticals companies in April.]]></description>
    </item>
    <item>
      <link>http://www.cphi-online.com/news/16318/GSK+Commences+Tender+Offer+to+Acquire+Human+Genome+Sciences.html</link>
      <title>GSK Commences Tender Offer to Acquire Human Genome Sciences</title>
      <author>joe | CPhI-Online.com</author>
      <category />
      <pubDate>Mon, 14 May 2012 15:30:27</pubDate>
      <description><![CDATA[GSK has commenced an unsolicited tender offer to acquire all of the outstanding common shares of Human Genome Sciences at a price of $13 per share.]]></description>
    </item>
    <item>
      <link>http://www.cphi-online.com/news/16309/AMRI+Posts+First+Quarter+2012+Results.html</link>
      <title>AMRI Posts First Quarter 2012 Results</title>
      <author>joe | CPhI-Online.com</author>
      <category />
      <pubDate>Thu, 10 May 2012 14:42:01</pubDate>
      <description><![CDATA[<img src="/Upload/news/2012_05/Nimg_12051014461FAA18.jpg" width="180" />The company's total revenue for the first quarter of 2012 was $53.7 million, a decrease of 6% compared to total revenue of $56.9 million reported in the first quarter of 2011.]]></description>
    </item>
    <item>
      <link>http://www.cphi-online.com/news/16310/BASF+Acquires+Equateq+for+Fatty+Acids+Portfolio.html</link>
      <title>BASF Acquires Equateq for Fatty Acids Portfolio</title>
      <author>joe | CPhI-Online.com</author>
      <category />
      <pubDate>Thu, 10 May 2012 14:58:54</pubDate>
      <description><![CDATA[<img src="/Upload/news/2012_05/Nimg_12051015030C46D2.jpg" width="180" />BASF says highly concentrated omega-3 fatty acids are a global growing market and increasing consumer awareness of the health benefits of omega-3 will see double-digit growth in the years to come.]]></description>
    </item>
    <item>
      <link>http://www.cphi-online.com/news/16303/Bayer+Yakuhin+%26+Santen+Enter+Agreement+for+Eylea+Injections.html</link>
      <title>Bayer Yakuhin &amp; Santen Enter Agreement for Eylea Injections</title>
      <author>joe | CPhI-Online.com</author>
      <category />
      <pubDate>Wed, 09 May 2012 09:13:19</pubDate>
      <description><![CDATA[Bayer Yakuhin and Santen will team up to promote Eylea in Japan.]]></description>
    </item>
    <item>
      <link>http://www.cphi-online.com/news/16294/Affymetrix+%26+eBioscience+Amend+Definitive+Merger+Agreement.html</link>
      <title>Affymetrix &amp; eBioscience Amend Definitive Merger Agreement</title>
      <author>joe | CPhI-Online.com</author>
      <category />
      <pubDate>Mon, 07 May 2012 10:57:53</pubDate>
      <description><![CDATA[<img src="/Upload/news/2012_05/Nimg_1205071102A7C10E.jpg" width="180" />Under the terms of the amended agreement, Affymetrix will acquire eBioscience for $315 million in cash subject to usual adjustments.]]></description>
    </item>
    <item>
      <link>http://www.cphi-online.com/news/16300/NIH+And+Industry+Team+up+to+Find+Uses+for+Abandoned+Drugs.html</link>
      <title>NIH And Industry Team up to Find Uses for Abandoned Drugs</title>
      <author>joe | CPhI-Online.com</author>
      <category />
      <pubDate>Mon, 07 May 2012 16:45:39</pubDate>
      <description><![CDATA[Pfizer, AstraZeneca and Lilly will make dozens of compounds available for the project.]]></description>
    </item>
    <item>
      <link>http://www.cphi-online.com/news/16301/Novartis+to+Acquire+Dermatology+Company+Fougera.html</link>
      <title>Novartis to Acquire Dermatology Company Fougera</title>
      <author>joe | CPhI-Online.com</author>
      <category />
      <pubDate>Mon, 07 May 2012 16:48:57</pubDate>
      <description><![CDATA[Sandoz, the generics division of Novartis, is to acquire dermatology specialist Fougera at a transaction value of $1.525 billion.]]></description>
    </item>
    <item>
      <link>http://www.cphi-online.com/news/16293/Sartorius+Stedim+Biotech+Signs+Sales+Agreement+with+c-LEcta.html</link>
      <title>Sartorius Stedim Biotech Signs Sales Agreement with c-LEcta</title>
      <author>joe | CPhI-Online.com</author>
      <category />
      <pubDate>Fri, 04 May 2012 16:58:03</pubDate>
      <description><![CDATA[The two firms have signed a worldwide sales and distribution agreement for c-LEcta’s proprietary Serratia marcescens nuclease for biopharmaceutical applications.]]></description>
    </item>
    <item>
      <link>http://www.cphi-online.com/news/16287/GSK+%26+Yale+Team+up+for+Drug+Discovery.html</link>
      <title>GSK &amp; Yale Team up for Drug Discovery</title>
      <author>joe | CPhI-Online.com</author>
      <category />
      <pubDate>Thu, 03 May 2012 09:37:08</pubDate>
      <description><![CDATA[GSK and Yale will work together to develop an entirely new class of drugs based on PROTACs technology.]]></description>
    </item>
    <item>
      <link>http://www.cphi-online.com/news/16279/Mergers+%26+Acquisitions+Activity+%22Lower+Than+Expected'+in+2011.html</link>
      <title>Mergers &amp; Acquisitions Activity "Lower Than Expected' in 2011</title>
      <author>joe | CPhI-Online.com</author>
      <category />
      <pubDate>Wed, 02 May 2012 09:31:54</pubDate>
      <description><![CDATA[The latest report from BioWorld reveals that M&A activity was more subdued than expected in 2011, while the number of biopharmaceutical collaborations declined.]]></description>
    </item>
    <item>
      <link>http://www.cphi-online.com/news/16280/Jazz+Pharmaceuticals+to+Acquire+EUSA+Pharma.html</link>
      <title>Jazz Pharmaceuticals to Acquire EUSA Pharma</title>
      <author>joe | CPhI-Online.com</author>
      <category />
      <pubDate>Wed, 02 May 2012 09:43:01</pubDate>
      <description><![CDATA[Jazz Pharmaceuticals and EUSA Pharma have announced that Jazz Pharmaceuticals has agreed to acquire the specialty pharmaceutical company for $650 million in cash and a potential $50 million milestone payment.]]></description>
    </item>
    <item>
      <link>http://www.cphi-online.com/news/16281/Watson+to+Become+Third+Largest+Global+Generics+Company+Following+Actavis+Takeover.html</link>
      <title>Watson to Become Third Largest Global Generics Company Following Actavis Takeover</title>
      <author>joe | CPhI-Online.com</author>
      <category />
      <pubDate>Wed, 02 May 2012 09:45:07</pubDate>
      <description><![CDATA[Watson Pharmaceuticals and Actavis Group have announced that Watson is buying the generic drugmaker.]]></description>
    </item>
    <item>
      <link>http://www.cphi-online.com/news/16283/NHS+Restructuring+May+Affect+UK+Pharma.html</link>
      <title>NHS Restructuring May Affect UK Pharma</title>
      <author>joe | CPhI-Online.com</author>
      <category />
      <pubDate>Wed, 02 May 2012 09:53:02</pubDate>
      <description><![CDATA[An expert has claimed that the NHS overhaul taking place in England will have a knock-on effect on the pharmaceutical industry.]]></description>
    </item>
  </channel>
</rss>
